Third-line H. pylori eradication therapy with sitafloxacin-including regimen

Third-line H. pylori eradication therapy with sitafloxacin-including regimen - H. pylori eradication therapy with sitafloxacin-including regimen

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001558

Enrollment

Registered

2008-12-11

Start date

2008-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with H. pylori eradication failure after the second-line regimen

Interventions

H. pylori eradication therapy with sitafloxacin-including regimen

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with H. pylori eradication failure after obtaining the informed consent.

Exclusion criteria

Exclusion criteria: penicillin or quinolone allergy rabeprazole allergy severe liver dysfunction, renal dysfunction pregnancy or possibly pregnancy cases with unsuitable recognition by doctors

Design outcomes

Primary

Measure	Time frame
Eradication rate of H. pylori by sitafloxacin-including regimen	—

Secondary

Measure	Time frame
MIC of sitafloxacin, gyrA mutation of H. pylori	—

Countries

Japan

Contacts

Public ContactHidekazu Suzuki

Keio University School of Medicine Division of Gastroenterology and Hepatology, Department of Internal Medicine

hsuzuki@sc.itc.keio.ac.jp03-5363-3914

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026